biostudies-literatureUnknown38(5)McEwan PAstraZeneca<h4>Background</h4>The Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial assessed dapagliflozin versus placebo, in addition to standard therapy, in patients with chronic kidney disease (CKD) and albuminuria, and was terminated prematurely due to overwhelming efficacy. The study objective was to model the long-term clinical outcomes of DAPA-CKD beyond the trial follow-up.<h4>Methods</h4>A Markov model extrapolated event incidence per 1000 patients and CKD progression rates for patients receiving dapagliflozin or placebo over a 10-year time horizon. We derived treatment-specific CKD stage transition matrices using DAPA-CKD trial data. We extrapolated relevant efficacy endpoints using parametric survival equations for all-cause mortality and generalizNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association1260-1270https://www.ebi.ac.uk/biostudies/studies/S-EPMC10157747biostudies-literatureExtrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis.PMC10157747Sjostrom CDNolan SMcMurray JJVRossing PMcEwan PWheeler DCCorrea-Rotter RChertow GMBoyce RStefansson BHeerspink HJLSanchez JJGfalseExtrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis.<h4>Background</h4>The Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial assessed dapagliflozin versus placebo, in addition to standard therapy, in patients with chronic kidney disease (CKD) and albuminuria, and was terminated prematurely due to overwhelming efficacy. The study objective was to model the long-term clinical outcomes of DAPA-CKD beyond the trial follow-up.<h4>Methods</h4>A Markov model extrapolated event incidence per 1000 patients and CKD progression rates for patients receiving dapagliflozin or placebo over a 10-year time horizon. We derived treatment-specific CKD stage transition matrices using DAPA-CKD trial data. We extrapolated relevant efficacy endpoints using parametric survival equations for all-cause mortality and generaliz2023-01-01T00:00:00Z2023 May2025-06-28T03:06:20.557Z2025-04-04T14:44:42.537ZS-EPMC101577473630161710.1093/ndt/gfac280